| |
| |
|
| Insider
Information: |
Forbes William P |
| Relationship: |
|
| City: |
Raleigh |
| State: |
NC |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
92,729 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$233,290 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
92,729 |
|
|
| Total
Value |
$233,290 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
0
|
|
Stock
price went up :
|
2
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
2.0
|
0.0
|
| Percentage
Gain/Loss : |
 195.2%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Salix Pharmaceuticals Ltd |
SLXP |
President, Medical, R&... |
2015-04-01 |
0 |
2006-07-13 |
0 |
Premium* |
|
|
Beyond Air Ord Shs |
XAIR |
Director |
2023-03-17 |
9,855 |
2023-03-17 |
0 |
Premium* |
|
|
Heron Therapeutics Inc |
HRTX |
|
2024-04-19 |
82,874 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
55 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2023-03-17 |
4 |
B |
$6.46 |
$32,300 |
D/D |
5,000 |
9,855 |
2.39 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2011-05-16 |
4 |
OE |
$17.53 |
$350,600 |
D/D |
20,000 |
100,355 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2011-05-16 |
4 |
S |
$40.35 |
$806,986 |
D/D |
(20,000) |
80,355 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2011-07-01 |
4 |
D |
$39.83 |
$366,914 |
D/D |
(9,212) |
71,143 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2011-07-07 |
4 |
AS |
$39.60 |
$514,764 |
D/D |
(13,000) |
58,143 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2012-01-17 |
4 |
OE |
$17.53 |
$19,616 |
D/D |
1,119 |
56,756 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2012-01-17 |
4 |
AS |
$50.06 |
$56,016 |
D/D |
(1,119) |
55,637 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2012-01-18 |
4 |
AS |
$50.00 |
$6,250 |
D/D |
(125) |
55,637 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2012-01-18 |
4 |
OE |
$17.53 |
$2,191 |
D/D |
125 |
55,762 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2012-02-13 |
4 |
AS |
$50.00 |
$214,850 |
D/D |
(4,297) |
55,637 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2012-02-13 |
4 |
OE |
$17.53 |
$75,326 |
D/D |
4,297 |
59,934 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2012-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
20,713 |
76,350 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2012-05-08 |
4 |
OE |
$17.53 |
$175,300 |
D/D |
10,000 |
86,350 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2012-05-08 |
4 |
AS |
$51.35 |
$516,139 |
D/D |
(10,000) |
76,350 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2012-07-02 |
4 |
D |
$54.44 |
$223,585 |
D/D |
(4,107) |
72,243 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2013-01-02 |
4 |
D |
$40.47 |
$204,454 |
D/D |
(5,052) |
67,191 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2013-04-10 |
4 |
AS |
$49.37 |
$428,186 |
D/D |
(8,673) |
71,518 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2013-04-10 |
4 |
OE |
$17.53 |
$227,890 |
D/D |
13,000 |
80,191 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2013-04-18 |
4 |
A |
$48.70 |
$1,156,187 |
D/D |
23,741 |
95,259 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2013-07-01 |
4 |
D |
$66.15 |
$319,835 |
D/D |
(4,835) |
90,424 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2013-07-24 |
4 |
OE |
$17.53 |
$210,360 |
D/D |
12,000 |
102,424 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2013-07-24 |
4 |
AS |
$69.91 |
$851,130 |
D/D |
(12,000) |
90,424 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2014-01-02 |
4 |
D |
$89.94 |
$796,059 |
D/D |
(8,851) |
81,573 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2014-01-08 |
4 |
OE |
$17.53 |
$140,240 |
D/D |
8,000 |
89,573 |
0 |
- |
|
| SLXP |
Salix Pharmaceuticals Ltd |
EVP Research&Devel & CDO |
• – – |
2014-01-08 |
4 |
AS |
$90.06 |
$720,480 |
D/D |
(8,000) |
81,573 |
0 |
- |
|
55 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
